First report card on biosimilars in oncology
(George Washington University) In a Policy Review in The Lancet Oncology, Y. Tony Yang, a professor at the George Washington University School of Nursing and Milken Institute School of Public Health, along with his co-authors, identify factors preventing the effective launch of oncology biosimilars in the United States, including the struggle to garner market share and fighting patent litigation lawsuits across the country.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cancer & Oncology | International Medicine & Public Health | Lawsuits | Legislation | Nurses | Nursing | USA Health | Washington University